Trial Profile

A Pilot/Exploratory Translational Study to Evaluate Response to Dostarlimab and Pembrolizumab in Patient-derived Organoids and by Zirconium-89 Labelled Programmed Death Ligand 1 Positron Emission Tomography in Participants With Recurrent Non-small Cell Lung Cancer

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Durvalumab (Primary) ; Pembrolizumab (Primary) ; Radiopharmaceutical diagnostics (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Diagnostic use
Sponsors GSK

19 Mar 2025 Planned End Date changed from 1 Jun 2028 to 30 Jun 2028.
19 Mar 2025 Planned primary completion date changed from 16 Dec 2027 to 14 Jan 2028.
19 Mar 2025 Planned initiation date changed from 28 Feb 2025 to 31 Mar 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com